-5%
Alunib 90mg Tablet is a targeted therapy addressing the unique needs of NSCLC patients with specific genetic mutations driving cancer growth.
- Alunib 90mg Tablet (Brigatinib) offers hope and transformation for those facing non-small cell lung cancer (NSCLC).
- Jenphar Bangladesh Ltd. is a trusted source for this targeted oral medication designed to address specific genetic mutations in metastatic NSCLC.
- Clinical trials have shown significant enhancement in progression-free survival compared to traditional chemotherapy.
- Offers new hope for patients who may not have responded well to previous treatments.
- Alunib 90mg Tablet is a targeted therapy addressing the unique needs of NSCLC patients with specific genetic mutations driving cancer growth.‘s oral form provides convenience, eliminating the need for frequent hospital visits.
- Administered at home for a more manageable and less disruptive treatment process.
- Generally well-tolerated, Alunib 90mg Tablet’s benefits are carefully weighed against potential risks by oncologists.
- Consultation with a healthcare provider is crucial for a personalized approach to treatment.
- Alunib 90mg Tablet should only be taken under the guidance of a qualified oncologist with expertise in lung cancer treatment.
- Individual medical condition assessment, tests, and treatment alignment are determined through consultation.
- Trepmac 90 mg has the potential to reshape NSCLC treatment, offering hope and progress.
- Information is foundational; consult with a healthcare professional for a personalized treatment plan.